Letrozol Synthon

Letrozole, the active ingredient in Letrozol Synthon, is an aromatase inhibitor presented as a tablet for oral use. It is used in the treatment of hormone receptor‑positive breast cancer in postmenopausal women and in metastatic breast cancer. GNH USA supplies Letrozol Synthon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Letrozole is an aromatase inhibitor used in breast cancer therapy, acting on estrogen‑dependent pathways. - Hormone receptor‑positive early breast cancer (adjuvant): reduces recurrence risk after surgery. - Metastatic hormone receptor‑positive breast cancer (first‑line): slows disease progression in postmenopausal women. - Recurrent hormone receptor‑positive breast cancer: provides disease control after prior therapy.

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: aching in joints or muscles. - Fatigue: persistent tiredness. - Nausea: mild to moderate upset stomach. - Headache: pressure or throbbing pain. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated enzymes. - Bone fractures: increased risk of osteoporosis‑related breaks. - Pulmonary embolism: sudden shortness of breath, chest pain. - Severe allergic reactions: rash, swelling, anaphylaxis. - QT interval prolongation: cardiac rhythm disturbances. - Stevens‑Johnson syndrome: severe skin blistering.

Before initiating Letrozole therapy, several safety considerations should be observed. - Assess bone health: evaluate risk of osteoporosis and consider calcium/vitamin D supplementation. - Monitor liver function: perform baseline and periodic liver enzyme tests. - Check lipid profile: estrogen reduction may affect cholesterol levels. - Contraindicated in pregnancy: Letrozole is category X and must not be used by pregnant women. - Use caution in cardiovascular disease: monitor for thromboembolic events. - Store at ambient temperature: keep in the original pack, protect from moisture.

Letrozole can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce Letrozole levels. - Estrogen‑containing hormone therapy: antagonizes therapeutic effect. - Tamoxifen: combined use may diminish anti‑estrogen activity. - Warfarin: increased anticoagulant effect, risk of bleeding.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluoxetine): may modestly raise Letrozole concentrations. - Statins: potential for additive liver toxicity. - Antihypertensives: monitor blood pressure changes. - Glucocorticoids: may affect bone health when combined.